Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Kalaris Therapeutics, Inc.

Contributing Author

Recent Articles by Kalaris Therapeutics, Inc.

Aug-31
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference KLRS GlobeNewswire
Aug-11
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates KLRS GlobeNewswire
Jul-20
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer KLRS -8.68% GlobeNewswire
Jul-17
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts KLRS GlobeNewswire
Jul-06
Kalaris Appoints Laurie Keating to Board of Directors KLRS GlobeNewswire
Jun-23
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling KLRS GlobeNewswire
Jun-12
Kalaris to Present at Clinical Trials at the Summit 2026 KLRS GlobeNewswire
May-12
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates KLRS GlobeNewswire
Jan-28
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting KLRS GlobeNewswire
Dec-17
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement KLRS +20.32% GlobeNewswire
Dec-17
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD KLRS +20.32% GlobeNewswire
Nov-12
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates KLRS GlobeNewswire
Nov-03
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer KLRS GlobeNewswire
Oct-30
Kalaris to Present at Stifel 2025 Annual Healthcare Conference KLRS GlobeNewswire
Sep-15
UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration KLRS KLRS +35.04% GlobeNewswire
Sep-15
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration KLRS GlobeNewswire
Aug-13
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates KLRS -8.43% GlobeNewswire
Jun-02
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference KLRS GlobeNewswire
May-23
Kalaris to Participate at Stifel Ophthalmology Forum KLRS GlobeNewswire
May-14
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights KLRS GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)